Senior Leadership are individuals with the requisite skill sets that in their totality, provide a balanced and complete perspective on our Cancer Center to ensure its optimal growth, function, resource utilization, and intra- and inter-programmatic interactions. These individuals also represent relevant aspects of Cancer Center affairs to the various clinical and research entities that comprise our matrix environment to ensure that the Cancer Center interacts to best advantage and can best capitalize on available external resources. Leadership includes the Cancer Center Executive Director (Dr. Curiel) and Deputy Director (Dr. Giles), our three scientific Associate Directors, Dr. Slaga (Basic and Translational Research), Dr. Naylor (Shared Resources and Internal Education) and Dr. Pollock (Cancer Prevention and Control). Dr. Ramirez serves as Senior Leadership owing to her directorship of the Institute for Health Promotion Research, which serves a critical cancer prevention and Hispanic outreach function for our Cancer Center. We also have an interim Associate Director of Administration with greatly augmented authority and a clear Senior Leadership role as requested in the prior review. A national search for a permanent Associate Director of Administration is undenway, with the expectation that the permanent position will be filled by the time of the site visit. The Senior Leadership ensures that our Cancer Center discharges its public trust through appropriate stewardship of NCI, NIH and related, institutional and philanthropic dollars to translate discoveries into practical applications that provide for the clinical and research cancer care needs of San Antonio, South Texas and the nation. All Senior Leadership members sit on the Executive Committee and other important committees that set current Cancer Center agendas, plan for future growth, challenges and opportunities and help set budgets, recruiting pnorities and scientific agendas that meet these various needs. Support is requested for Dr. Curiel (50%), Dr. Giles (5%), Dr. Naylor (10%), Dr. Ramirez (10%), Dr. Slaga (20%), and Ms. McCarroll (50%). Some Senior Leadership also serve as Program Leaders, but generally those duties are co-shared with Senior Leadership in terms of financial support. Thus, most support for the totality'of the efforts of these individuals comes from Senior Leadership, freeing our scare resources in the budget for additional, constructive uses in our Cancer Center.
Senior Leadership provides a balanced and complete perspective on our Cancer Center to ensure its optimal growth, function, resource utilization, and intra- and inter-programmatic interactions. These individuals also represent relevant aspects of Cancer Center affairs to the various clinical and basic science entities that comprise our matrix environment to ensure that the Cancer Center interacts to best advantage and can best capitalize on available external resources. This group ensures the success and vitality of our Cancer Center and keeps us poised to capitalize on opportunities, such as Proposition 15 dollars.
|Yu, Xiaojie; Zhang, Yiqiang; Cavazos, David et al. (2018) miR-195 targets cyclin D3 and survivin to modulate the tumorigenesis of non-small cell lung cancer. Cell Death Dis 9:193|
|Chen, Chen; Zhao, Shujie; Karnad, Anand et al. (2018) The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 11:64|
|Abbott, Jamie A; Meyer-Schuman, Rebecca; Lupo, Vincenzo et al. (2018) Substrate interaction defects in histidyl-tRNA synthetase linked to dominant axonal peripheral neuropathy. Hum Mutat 39:415-432|
|Guo, Jiayan; Kim, Hong Seok; Asmis, Reto et al. (2018) Interactions of ? tubulin isotypes with glutathione in differentiated neuroblastoma cells subject to oxidative stress. Cytoskeleton (Hoboken) 75:283-289|
|Liss, Michael A; Chen, Yidong; Rodriguez, Ronald et al. (2018) Immunogenic Heterogeneity of Renal Cell Carcinoma With Venous Tumor Thrombus. Urology :|
|Zhu, Haiyan; Xia, Lu; Shen, Qi et al. (2018) Differential effects of GLI2 and GLI3 in regulating cervical cancer malignancy in vitro and in vivo. Lab Invest 98:1384-1396|
|Zeno, Wade F; Baul, Upayan; Snead, Wilton T et al. (2018) Synergy between intrinsically disordered domains and structured proteins amplifies membrane curvature sensing. Nat Commun 9:4152|
|Mahalingam, Devalingam; Goel, Sanjay; Aparo, Santiago et al. (2018) A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 10:|
|Yu, Xiaojie; Zhang, Yiqiang; Ma, Xiuye et al. (2018) miR-195 potentiates the efficacy of microtubule-targeting agents in non-small cell lung cancer. Cancer Lett 427:85-93|
|Ankerst, Donna P; Goros, Martin; Tomlins, Scott A et al. (2018) Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. Eur Urol Focus :|
Showing the most recent 10 out of 989 publications